Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study.

BACKGROUND The risk of venous thromboembolism (VTE) in women taking combined oral contraceptives (COCs) is attributed to changes in coagulation and fibrinolysis. Their impact may be greater in women with preexistent thrombophilic defects. METHODS We assessed the effects of COCs on absolute VTE risk in women with single or multiple thrombophilic defects in a retrospective family cohort study. Female relatives of probands with VTE and hereditary deficiencies of protein S, protein C, or antithrombin were tested for known thrombophilic defects, including the index deficiency. Absolute incidences of VTE were compared in deficient vs nondeficient women, in deficient and nondeficient women who ever or never used COCs, and in deficient and nondeficient women with 0, 1, or more than 1 other thrombophilic defect during exposure to COCs. RESULTS Of 222 women, 135 (61%) ever used COCs. Overall, annual incidences of VTE were 1.64% and 0.18% in deficient and nondeficient women, respectively; the adjusted relative risk was 11.9 (95% confidence interval, 3.9-36.2). The risk was comparable in deficient ever and never users (1.73% vs 1.54%). Annual incidences during actual COC use were 4.62% in deficient women and 0.48% in nondeficient women; the relative risk was 9.7 (95% confidence interval, 3.0-42.4). The incidence increased by concomitant thrombophilic defects, from 3.49% to 12.00% in deficient women and from 0% to 3.13% in nondeficient women. CONCLUSIONS Women with hereditary deficiencies of protein S, protein C, or antithrombin are at high risk of VTE during use of COCs, particularly when other thrombophilic defects are present. They have VTE at a younger age, but the overall risk is not increased by COCs.

[1]  H. Kluin-Nelemans,et al.  The Pathogenesis of Venous Thromboembolism: Evidence for Multiple Interrelated Causes , 2006, Annals of Internal Medicine.

[2]  H. Kluin-Nelemans,et al.  Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test‐based classification , 2005, British journal of haematology.

[3]  F R Rosendaal,et al.  Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT) , 2005, Journal of thrombosis and haemostasis : JTH.

[4]  F. Bernardi,et al.  Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. , 2002, European heart journal.

[5]  M. Prins,et al.  Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. , 2002, Haematologica.

[6]  J. Vandenbroucke,et al.  Family history and risk of venous thromboembolism with oral contraception , 2001, BMJ : British Medical Journal.

[7]  Diederick E Grobbee,et al.  Third generation oral contraceptives and risk of venous thrombosis: meta-analysis , 2001, BMJ : British Medical Journal.

[8]  J. Vandenbroucke,et al.  Family history and risk of venous thromboembolism with oral contraception. Family history is important tool. , 2001, BMJ.

[9]  J. Fontcuberta,et al.  Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene. , 2001, Haematologica.

[10]  M. Prins,et al.  A Randomized Cross-over Study on the Effects of Levonorgestrel- and Desogestrel-containing Oral Contraceptives on the Anticoagulant Pathways , 2000, Thrombosis and Haemostasis.

[11]  M. Prins,et al.  Effects on Coagulation of Levonorgestrel- and Desogestrel-containing Low Dose Oral Contraceptives: a Cross-over Study , 2000, Thrombosis and Haemostasis.

[12]  D. Corella,et al.  Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. , 2000, Haematologica.

[13]  P. Mannucci,et al.  Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[14]  M. Prins,et al.  Incidence of Venous Thromboembolism in Families with Inherited Thrombophilia , 1999, Thrombosis and Haemostasis.

[15]  B. Bruggeman,et al.  Reliable genotyping of the G-20210-A mutation of coagulation factor II (prothrombin). , 1998, Clinical chemistry.

[16]  M. Prins,et al.  The Incidence of Venous Thromboembolism in Family Members of Patients with Factor V Leiden Mutation and Venous Thrombosis , 1998, Annals of Internal Medicine.

[17]  A. Tosetto,et al.  Validated questionnaire for the identification of previous personal or familial venous thromboembolism. , 1996, American journal of epidemiology.

[18]  P. Reitsma,et al.  Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. , 1996, The New England journal of medicine.

[19]  T. Farley,et al.  Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease , 1995 .

[20]  World Health Organization Collaborative Study of Cardiov Contraception.  Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease , 1995, The Lancet.

[21]  H. Jick,et al.  Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components , 1995, The Lancet.

[22]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[23]  B. Lämmle,et al.  Thrombotic Risk of Women with Hereditary Antithrombin III-, Protein C- and Protein S-Deficiency Taking Oral Contraceptive Medication , 1994, Thrombosis and Haemostasis.

[24]  B. Lindblad,et al.  A prospective study of the incidence of deep‐vein thrombosis within a defined urban population , 1992, Journal of internal medicine.

[25]  D. Hosmer,et al.  A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. , 1991, Archives of internal medicine.

[26]  S. Machin,et al.  Guidelines for Testing and Revised Criteria for Lupus Anticoagulants , 1991, Thrombosis and Haemostasis.

[27]  D. Kennedy,et al.  Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. , 1990, International journal of epidemiology.

[28]  H. Büller,et al.  Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. , 1990, The New England journal of medicine.

[29]  S. Daeschner.  Pulmonary embolism. , 1988, Nursing.

[30]  Y. Sako,et al.  Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. , 1987, Journal of chromatography.

[31]  D. W. Calhoun,et al.  Oral contraceptives and thromboembolic disease. , 1968, JAMA.